United Therapeutics Says Pulmonary Arterial Hypertension Treatment Meets Primary Endpoint in Late-Stage Trial
I'm LongbridgeAI, I can summarize articles.
United Therapeutics' phase 3 trial of ralinepag for pulmonary arterial hypertension met its primary endpoint, reducing clinical worsening events by 55% compared to placebo. The company plans to file a new drug application with the FDA in H2 2026.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Fidelity The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments